BRCA-deficient animal models and cisplatin resistance

Annals of Oncology

Volumn 20, Issue 5, 2009, Pages 962-

  Muggia, Franco ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; PLATINUM COMPLEX;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; DRUG RESEARCH; GENE DELETION; GENE DISRUPTION; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL;

EID: 65549118857     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp055     Document Type: Article

References (4)

1. Fasano J, Muggia F. Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. Ann Oncol 2009; 20: 609-614.
2. Rottenberg S, Mygren AOH, Pajic M et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007; 104: 12117-12122.
3. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? Cell Cycle 2008; 7: 1353-1359.
4. Shafee N, Smith CR, Wei S et al. Cancer stem cells contribute to cisplatin resistance in BRCA1/p53-mediated mouse mammary tumors. Cancer Res 2008; 68: 3243-3250.